Latest information and updates about COVID-19 (coronavirus) from McMaster University
Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster Logo McMaster logo

Department of Defense (DoD): Peer Reviewed Alzheimer’s Research Program (PRARP) Funding Opportunities for Fiscal Year 2021 (FY21)

Research Admin Offices:

  • ROADS
  • HRS

Funding Type:

Grant

Value:

Funding Details:

  • Convergence Science Research Award:
    • Level I – Maximum funding of $225,000 in direct and indirect costs for a maximum of 3 years.
    • Level II – Maximum funding of $500,000 in direct and indirect costs for a maximum of 3 years.
  • Innovation in Care and Support Award:
    • Level I – Maximum funding of $225,000 in direct and indirect costs for a maximum of 3 years.
    • Level II – Maximum funding of $500,000 in direct and indirect costs for a maximum of 3 years.
  • Research Partnership Award – Maximum funding of $1.3M in total costs for a maximum of 3 years.
  • Accelerating Diagnostic Research Award – Maximum funding of $2.8M in total costs for a maximum of 4 years.
  • Leveraging Approaches for Innovation in Care and Support Award – Maximum funding of $2.8M in total costs for a maximum of 4 years.

Disciplines:

  • Health Sciences

Sponsors:

Deadlines:

Internal Deadline:

June 7, 2021

Sponsor Deadline:

July 21, 2021

Additional Dates:

  • Internal LOI Due to ROADS - June 7, 2021
  • Sponsor - External LOI Deadline - June 14, 2021
  • Internal HRS Deadline - Draft Application - July 7, 2021
  • Internal ROADS Deadline - Draft Application - July 14, 2021

Description:

The PRARP was initiated in 2011 to address the long-term consequences of TBI as they pertain to Alzheimer’s disease (AD). In 2016, the program was expanded to include AD-related dementias (ADRD) research as it pertains to TBI. In 2021, the program expanded its focus to include the spectrum of AD and ADRD risk factors that may affect military health. The program emphasizes not only basic research related to understanding and diagnosing the molecular basis of dementia after military service, but also tools and strategies which can improve the quality of life of individuals living with AD or ADRD by their implementation in care settings.

LOI Deadline: June 14, 2021 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: July 7, 2021
Sponsor Deadline: July 21, 2021

Convergence Science Research Award

The intent of the FY21 PRARP CSRA is to support innovative and impactful efforts to generate research resources, tools, and new avenues of investigation for researchers and practitioners in the health sciences. The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the context of the PRARP’s mission and vision. The application should also demonstrate the study team’s experience in both military risk factor-related research and AD/ADRD as suited to the proposed work. The research innovation and impact for the FY21 PRARP CSRA are expected to benefit the military, Veteran, and civilian communities. FY21 PRARP CSRA applications must be innovation- and impact-based.

Innovation in Care and Support Award

The intent of the FY21 PRARP In CASA is to support innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with AD/ADRD. The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the context of the PRARP’s mission and vision. This can include innovations and research for symptom reduction (e.g., cognitive, behavioral, function, mood), resiliency factors, increasing or maintaining independence, and support for families and care providers. The application should also demonstrate the study team’s experience in both military risk factor-related research and AD/ADRD as suited to the proposed work. Given the patient-centered intent of the FY21 PRARP InCASA, animal research is prohibited. The research innovation and impact for the FY21 PRARP InCASA are expected to benefit the military, Veteran, and civilian communities. FY21 PRARP InCASA applications must be innovation- and impact-based.

Research Partnership Award

The intent of the FY21 PRARP RPA is to create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts as related to the PRARP’s mission (see Section II.A, Program Description). In addition to supporting basic research, FY21 PRARP RPA applications proposing preclinical or pre-validation research are acceptable. Applications that explore the Overarching Challenges of Quality of Life or Family and Care Support are encouraged. The application should also demonstrate the study team’s experience in both military risk factor-related research and AD/ADRD as suited to the proposed work. Projects addressing either the Quality of Life or Family and Care Support Overarching Challenges are prohibited from conducting animal research. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY21 PRARP RPA applications must be impact-based.

Accelerating Diagnostic Research Award

The intent of the FY21 PRARP ADRA is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY21 PRARP ADRA mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical endpoints. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. The FY21 PRARP ADRA does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to military risk factor-related research and AD/ADRD. As part of the application, the Principal Investigator (PI) should demonstrate that the study team has experience in both military risk factor-related research and AD/ADRD.

Leveraging Approaches for Innovation in Care and Support Award

The intent of the FY21 PRARP LEAP-InCASA is to support innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with AD/ADRD. The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the context of the PRARP’s mission and vision. This can include innovations and research for symptom reduction (e.g., cognitive, behavioral, function, mood), resiliency factors, increasing or maintaining independence, and support for families and care providers.

The FY21 PRARP LEAP-InCASA supports multi-institutional, harmonized research initiatives. As such, applications to the FY21 PRARP LEAP-InCASA require a Coordinating Center and a minimum of two Partnering Sites, representing at least three separate institutions within the application package. While the Coordinating Center provides overall infrastructure and support, each Partnering Site should develop its own unique research initiative that will be part of the overall project. The application should also demonstrate the study team’s experience in both military risk factor-related research and AD/ADRD as suited to the proposed work. Given the patient-centered intent of the FY21 PRARP LEAP-InCASA, animal research is prohibited.

Additional Program Information:

Convergence Science Research Award (CSRA)

Level I: Investigators at the postdoctoral level (e.g., research associates, fellows, medical residents, or equivalent) but below the level of Assistant Professor (or equivalent) at the time of the application submission deadline.

Mentor required.

Level II: The Principal Investigator (PI) must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.
Intent: To support innovative and impactful efforts to generate research resources, tools, and new avenues of investigation for researchers and practitioners in the health sciences.

Level I: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the mentor(s). The mentor(s) must possess qualifications, background, and experience in both the identified military risk factor and Alzheimer’s disease (AD)/AD-related dementias (ADRD) research.

Level II: Intended to support applicants from any field or discipline at or above the level of assistant professor (or equivalent) from any field or discipline. Study teams are expected to demonstrate relevant experience in both the identified military risk factor and AD/ADRD.

Applications must address one of the following FY21 PRARP Overarching Challenges:
• Foundational Research
• Paucity of Clinical Studies
• Diagnostics and Prognostics
• Epidemiology

Applications should address one of the following FY21 PRARP Military Risk Factors:
• Traumatic Brain Injury
• Neurophysiological/Neurobehavioral
• Vascular
• Inflammation
• Genetic
• Metabolic
• Sleep

Pharmacological interventions are specifically discouraged.
While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.
Research that focuses exclusively on chronic traumatic encephalopathy (CTE) research is prohibited.
Pharmacological interventions are specifically discouraged.
Chronic traumatic encephalopathy (CTE) research is prohibited. Preliminary data, while not required, are encouraged.

Value:
Level I:
• Maximum funding of $225,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.
Level II:
• Maximum funding of $500,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.
For Both Levels: Indirect costs may be proposed in accordance with the institution’s rate agreement.

Innovation in Care and Support Award (InCASA)

Level I: Investigators at the postdoctoral level (e.g., research associates, fellows, medical residents, or equivalent) but below the level of Assistant Professor (or equivalent) at the time of the application submission deadline.
• Mentor required. Level II: The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.
Intent: To support innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with AD/ADRD.
• Level I: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the mentor(s). The mentor(s) must possess qualifications, background, and experience in both the identified military risk factor and AD/ADRD.
• Level II: Intended to support applicants from any field or discipline at or above the level of assistant professor (or equivalent) from any field or discipline. Study teams are expected to demonstrate relevant experience in both the identified military risk factor and AD/ADRD.
Applications must address one of the following FY21 PRARP Overarching Challenges:
• Paucity of Clinical Studies
• Quality of Life
• Family and Care Support

Applications should address one of the following FY21 PRARP Military Risk Factors:
• Traumatic Brain Injury
• Neurophysiological/Neurobehavioral
• Modifiable Risk Factors
• Vascular
• Inflammation
• Genetic
• Metabolic
• Sleep

Pharmacological interventions are specifically discouraged.
Animal research is prohibited.
While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.
Research that focuses exclusively on CTE research is prohibited.

Value:
Level I:
• Maximum funding of $225,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.
Level II:
• Maximum funding of $500,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.
For Both Levels:
Indirect costs may be proposed in accordance with the institution’s rate agreement.

Research Partnership Award (RPA)

The initiating PI must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline. Each named Co-PI must be at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.
Intent: To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts as related to the PRARP’s mission. Applications must include clearly stated plans for interactions between/among the partners. The plans must include communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among all investigators and organizations participating in the project.
Applications must address one of the following FY21 PRARP Overarching Challenges:
• Foundational Research
• Paucity of Clinical Studies
• Diagnostics and Prognostics
• Epidemiology
• Quality of Life
• Family and Care Support

Applications should address at least one of the following FY21 PRARP Military Risk Factors:
• Traumatic Brain Injury
• Neurophysiological/Neurobehavioral
• Modifiable Risk Factors
• Vascular
• Inflammation
• Genetic
• Metabolic
• Sleep

Pharmacological interventions are specifically discouraged.
Preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are required. Research that focuses exclusively on CTE research is prohibited.

Value:
Funding limit is $1.3 million (M) in total costs over 3 years

Accelerating Diagnostics Research Award (ADRA)

The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.
Intent: To support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD.
Applications must address the following FY21 PRARP Overarching Challenge.
• Diagnostics and Prognostics
Applications must address one of the following FY21 PRARP Military Risk Factors:
• Traumatic Brain Injury
• Neurophysiological/Neurobehavioral
• Vascular
• Inflammation
• Genetic
• Metabolic

The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to the proposed military risk factor and AD/ADRD. The applicant must choose one biomarker category for the overall application:
• Imaging-Related
• Fluid-Based (e.g., cerebrospinal fluid, blood, or saliva)
• Retinal
• Wearable Devices
• Other

Studies focused on biomarker discovery are discouraged.
Pharmacological interventions are specifically discouraged.
Animal research is prohibited.
Preliminary data regarding the suitability of the biomarker(s) for further testing toward biomarker qualification is required.
Research that focuses exclusively on CTE research is prohibited.

Value: $2.8 M over 4 years

Leveraging Approaches for Innovation in Care and Support Award (LEAP-InCASA)

The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent) at the time of the application submission deadline.
Intent: To support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD.
Applications must address the following FY21 PRARP Overarching Challenge.
• Diagnostics and Prognostics
Applications must address one of the following FY21 PRARP Military Risk Factors:
• Traumatic Brain Injury
• Neurophysiological/Neurobehavioral
• Vascular
• Inflammation
• Genetic
• Metabolic

The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to the proposed military risk factor and AD/ADRD. The applicant must choose one biomarker category for the overall application:
• Imaging-Related
• Fluid-Based (e.g., cerebrospinal fluid, blood, or saliva)
• Retinal
• Wearable Devices
• Other

Studies focused on biomarker discovery are discouraged.
Pharmacological interventions are specifically discouraged.
Animal research is prohibited.
Preliminary data regarding the suitability of the biomarker(s) for further testing toward biomarker qualification is required.
Research that focuses exclusively on CTE research is prohibited.

Value: $2.8 M over 4 years

 

Eligibility:

Value:
Funding limit is $1.3 million (M) in total costs over 3 years

Resources:

 

Contact:

If you are applying from the Faculty of Health Sciences, please contract Health Research Services (HRS). If you are applying from any other Faculty, please contact Virginia Viscardi, Senior Advisor, ROADS.